Literature DB >> 32016048

The SONAR study-is there a future for endothelin receptor antagonists in diabetic kidney disease?

Avivit Cahn1, Simona Cernea2,3, Itamar Raz1.   

Abstract

Entities:  

Year:  2019        PMID: 32016048      PMCID: PMC6976431          DOI: 10.21037/atm.2019.09.117

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  22 in total

1.  Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

Authors:  Ofri Mosenzon; Stephen D Wiviott; Avivit Cahn; Aliza Rozenberg; Ilan Yanuv; Erica L Goodrich; Sabina A Murphy; Hiddo J L Heerspink; Thomas A Zelniker; Jamie P Dwyer; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Eri T Kato; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna Maria Langkilde; Marc S Sabatine; Itamar Raz
Journal:  Lancet Diabetes Endocrinol       Date:  2019-06-10       Impact factor: 32.069

2.  Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

Authors:  Hiddo J L Heerspink; Tom Greene; Hocine Tighiouart; Ron T Gansevoort; Josef Coresh; Andrew L Simon; Tak Mao Chan; Fan Fan Hou; Julia B Lewis; Francesco Locatelli; Manuel Praga; Francesco Paolo Schena; Andrew S Levey; Lesley A Inker
Journal:  Lancet Diabetes Endocrinol       Date:  2019-01-08       Impact factor: 32.069

3.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

Review 4.  Update on Diabetic Nephropathy: Core Curriculum 2018.

Authors:  Kausik Umanath; Julia B Lewis
Journal:  Am J Kidney Dis       Date:  2018-02-03       Impact factor: 8.860

5.  The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.

Authors:  Dick de Zeeuw; Blai Coll; Dennis Andress; John J Brennan; Hui Tang; Mark Houser; Ricardo Correa-Rotter; Donald Kohan; Hiddo J Lambers Heerspink; Hirofumi Makino; Vlado Perkovic; Yili Pritchett; Giuseppe Remuzzi; Sheldon W Tobe; Robert Toto; Giancarlo Viberti; Hans-Henrik Parving
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

6.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

7.  Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

Authors:  Vlado Perkovic; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Terrance D Barrett; Michele Weidner-Wells; Hsiaowei Deng; David R Matthews; Bruce Neal
Journal:  Lancet Diabetes Endocrinol       Date:  2018-06-21       Impact factor: 32.069

8.  Avosentan for overt diabetic nephropathy.

Authors:  Johannes F E Mann; Damian Green; Kenneth Jamerson; Luis M Ruilope; Susan J Kuranoff; Thomas Littke; Giancarlo Viberti
Journal:  J Am Soc Nephrol       Date:  2010-02-18       Impact factor: 10.121

9.  Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.

Authors:  Hiddo J L Heerspink; Dennis L Andress; George Bakris; John J Brennan; Ricardo Correa-Rotter; Jyotirmoy Dey; Fan Fan Hou; Dalane W Kitzman; Donald Kohan; Hirofumi Makino; John McMurray; Vlado Perkovic; Sheldon Tobe; Melissa Wigderson; Hans-Henrik Parving; Dick de Zeeuw
Journal:  Diabetes Obes Metab       Date:  2018-03-09       Impact factor: 6.577

10.  Baseline characteristics and enrichment results from the SONAR trial.

Authors:  Hiddo J L Heerspink; Dennis L Andress; George Bakris; John J Brennan; Ricardo Correa-Rotter; Fan Fan Hou; Dalane W Kitzman; Donald Kohan; Hirofumi Makino; John McMurray; Vlado Perkovic; Sheldon Tobe; Melissa Wigderson; Tingting Yi; Hans-Henrik Parving; Dick de Zeeuw
Journal:  Diabetes Obes Metab       Date:  2018-05-01       Impact factor: 6.577

View more
  3 in total

1.  Synthesis and Molecular Modelling Studies of New 1,3-Diaryl-5-Oxo-Proline Derivatives as Endothelin Receptor Ligands.

Authors:  Sebastiano Intagliata; Mohamed A Helal; Luisa Materia; Valeria Pittalà; Loredana Salerno; Agostino Marrazzo; Alfredo Cagnotto; Mario Salmona; Maria N Modica; Giuseppe Romeo
Journal:  Molecules       Date:  2020-04-17       Impact factor: 4.411

2.  Comprehensive analysis of diabetic nephropathy expression profile based on weighted gene co-expression network analysis algorithm.

Authors:  Alieh Gholaminejad; Mohammad Fathalipour; Amir Roointan
Journal:  BMC Nephrol       Date:  2021-07-02       Impact factor: 2.388

3.  Identification of hub genes in diabetic kidney disease via multiple-microarray analysis.

Authors:  Yumin Zhang; Wei Li; Yunting Zhou
Journal:  Ann Transl Med       Date:  2020-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.